Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?Zacks Investment Research • 07/10/25
Methode Electronics, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Thursday's Pre-Market SessionBenzinga • 07/10/25
Ultragenyx and Mereo BioPharma Announce UX143 Phase 3 Orbit Study for Osteogenesis Imperfecta Progressing to Final AnalysisGlobeNewsWire • 07/09/25
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman SyndromeZacks Investment Research • 06/30/25
Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman SyndromeGlobeNewsWire • 06/27/25
Ultragenyx (RARE) Up 9.6% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/05/25
Ultragenyx to Participate at Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewsWire • 06/03/25
Ultragenyx Underscores Continued Commitment to Rare Disease Innovation with 2024 Impact ReportGlobeNewsWire • 05/14/25
Ultragenyx (RARE) Reports Q1 Earnings: What Key Metrics Have to SayZacks Investment Research • 05/06/25
Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 04/30/25
Ultragenyx (RARE) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseZacks Investment Research • 04/24/25
Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?Zacks Investment Research • 04/10/25
Ultragenyx (RARE) Q4 Earnings: Taking a Look at Key Metrics Versus EstimatesZacks Investment Research • 02/13/25
Ultragenyx Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate UpdateGlobeNewsWire • 02/13/25
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate UpdateGlobeNewsWire • 02/06/25